Surgical Robotics Technology
THERACLION has announced that its latest generation SONOVEIN® ‘SpeedPulse’ feature is being tried on patients.
Major R&D breakthroughs in recent months
SONOVEIN® achieved a new level of maturity in 2024, with Theraclion maintaining its focus on ongoing R&D and innovation. Key progress has recently been made on the development of new functionalities, particularly in Artificial Intelligence, acoustics and 3D robotics, boosting clinical efficacy and treatment speed. These advancements will drive broader adoption in treatment centers, expanding the addressable market and reinforcing Theraclion’s mid-term growth potential.
SONOVEIN® ‘SpeedPulse’ significantly reduces treatment time
As part of these major enhancements, a clinical trial has started in Prague, Czech Republic, at the end of January 2025. The tested feature called ‘SpeedPulse’ integrates improved acoustics and therapeutic ultrasound pulsing, aiming at substantially increasing treatment speed. The trial will span over several months.
Prof. Jaroslav Strejček, head investigator of the trial, declared: “As an early adopter of the SONOVEIN®, I’m excited to see the SpeedPulse feature being developed. During the first patient treatments with the SpeedPulse, we have already observed dramatic potential for shortening the treatment duration. This innovation brings significant value to an already groundbreaking technology, further enhancing SONOVEIN®’s competitiveness against existing varicose veins treatment methods.”
The commercialization of SONOVEIN® ‘SpeedPulse’ is planned to start after the trial and completion of the regulatory approval process.
Source: Theraclion
